Supratentorial Neoplasms: Clinical Trials

10 trials for Supratentorial Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 unknown, 1 active not recruiting, 1 not yet recruiting. 10 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 310Completed 5, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1
Phase 21Unknown 1

Follow Supratentorial Neoplasms: new trials by email Literature Review of Supratentorial Neoplasms trials Research Report on Supratentorial Neoplasms

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours
Standard dose Intensity-Modulated Radiation Therapy (IMRT), Standard dose Proton Beam Therapy (PBT), Escalated dose Proton Beam Therapy (PBT) - Acromegaly Due to Pituitary Adenoma, Cushing's Disease
Phase 3Not yet recruitingUniversity College, London822026-09-012026-10-01
The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas
Radiotherapy plus temozolomide, Radiotherapy plus placebo - Pituitary Adenomas
Phase 2 / Phase 3UnknownPeking Union Medical College Hospital1502020-02-102020-01-28
Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma
Gamma knife radiosurgery, Lanreotide 60Mg Solution for Injection - Acromegaly Due to Pituitary Adenoma
Phase 3UnknownSamsung Medical Center902018-03-012018-03-01
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Pasireotide LAR - Acromegaly
Phase 3CompletedNovartis Pharmaceuticals1232015-03-312019-12-10
Cabergoline in Nonfunctioning Pituitary Adenomas
Cabergoline - Pituitary Adenoma, Nonfunctioning Pituitary Adenoma
Phase 3CompletedUniversity of Sao Paulo General Hospital1402015-02-012017-09-07
Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
Gallium-68 DOTATOC PET - Pituitary Tumours
Phase 3TerminatedGöteborg University222015-01-012022-03-31
Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas
cabergoline - Pituitary Neoplasms, Adenoma
Phase 3Active not recruitingSt. Olavs Hospital602014-11-012026-07-21
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
Pasireotide sub-cutaneous - Cushing's Disease
Phase 3CompletedNovartis Pharmaceuticals1042011-08-162018-06-19
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg - Acromegaly
Phase 3CompletedNovartis Pharmaceuticals1982010-07-192018-04-05
Anaesthesia for Supratentorial Tumor Resection
Comparison of two anesthetics protocol - Supratentorial Neoplasms
Phase 3CompletedAssistance Publique - Hôpitaux de Paris692006-11-012012-07-10

Narrower conditions

Pituitary Neoplasms (9)  ·  Acromegaly (5)  ·  Adenoma (2)  ·  Growth Hormone-Secreting Pituitary Adenoma (2)  ·  Pituitary ACTH Hypersecretion (2)  ·  Pituitary Diseases (2)  ·  Gigantism (1)  ·  Growth Disorders (1)

Broader conditions

Brain Diseases (10)  ·  Brain Neoplasms (10)  ·  Central Nervous System Diseases (10)  ·  Central Nervous System Neoplasms (10)  ·  Neoplasms (10)  ·  Neoplasms by Site (10)  ·  Nervous System Diseases (10)  ·  Nervous System Neoplasms (10)  ·  Endocrine Gland Neoplasms (9)  ·  Endocrine System Diseases (9)  ·  Hypothalamic Diseases (9)  ·  Hypothalamic Neoplasms (9)  ·  Pituitary Diseases (7)  ·  Hyperpituitarism (6)

Interventions

Cabergoline (2)  ·  pasireotide (2)  ·  Injections (1)  ·  Proton Therapy (1)  ·  Radiosurgery (1)  ·  Radiotherapy (1)  ·  Radiotherapy, Intensity-Modulated (1)  ·  Solutions (1)  ·  Temozolomide (1)  ·  lanreotide (1)

Sponsors

Novartis Pharmaceuticals (3)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Göteborg University (1)  ·  Peking Union Medical College Hospital (1)  ·  Samsung Medical Center (1)  ·  St. Olavs Hospital (1)  ·  University College, London (1)  ·  University of Sao Paulo General Hospital (1)

Countries

Brazil (4)  ·  France (3)  ·  Romania (3)  ·  Argentina (2)  ·  Belgium (2)  ·  Colombia (2)  ·  Germany (2)  ·  Italy (2)  ·  Norway (2)  ·  Russia (2)  ·  South Korea (2)  ·  Spain (2)  ·  Sweden (2)  ·  Turkey (Türkiye) (2)  ·  United Kingdom (2)

Top investigators

Michael Kosmin (1)  ·  Rafael L Batista, MD (1)  ·  Sven M Carlsen, prof md (1)

Results publications

PMID 23774117, PMID 25260838, PMID 25418156, PMID 27150495, PMID 30540568, PMID 31379734, PMID 32117045, PMID 32217809, PMID 35954244, PMID 36856733, PMID 8512094

NIH funding

2014 (1)